Strides Pharma Science Limited (STAR.NS)
- Previous Close
843.60 - Open
840.00 - Bid 884.90 x --
- Ask 885.00 x --
- Day's Range
840.00 - 887.15 - 52 Week Range
330.00 - 887.15 - Volume
662,794 - Avg. Volume
534,660 - Market Cap (intraday)
81.331B - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
-- - EPS (TTM)
-16.79 - Earnings Date May 23, 2024 - May 27, 2024
- Forward Dividend & Yield 1.50 (0.18%)
- Ex-Dividend Date Aug 4, 2023
- 1y Target Est
837.50
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company has a strategic partnership with Orbicular Pharmaceutical Technologies Private Limited to develop, manufacture, and commercialize nasal sprays. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
www.strides.com2,850
Full Time Employees
March 31
Fiscal Year Ends
Sector
Related News
Performance Overview: STAR.NS
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: STAR.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: STAR.NS
Valuation Measures
Market Cap
77.53B
Enterprise Value
101.14B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.97
Price/Book (mrq)
3.78
Enterprise Value/Revenue
2.61
Enterprise Value/EBITDA
28.91
Financial Highlights
Profitability and Income Statement
Profit Margin
-2.49%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
39.53B
Net Income Avi to Common (ttm)
-1.52B
Diluted EPS (ttm)
-16.79
Balance Sheet and Cash Flow
Total Cash (mrq)
3.26B
Total Debt/Equity (mrq)
140.19%
Levered Free Cash Flow (ttm)
--
Research Analysis: STAR.NS
Company Insights: STAR.NS
STAR.NS does not have Company Insights